October 29, 2024
Recently, BOCG's portfolio company, Ribo Life Science, announces that it received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3.
September 20, 2024
On September 11, 2024, the Hong Kong International Biotechnology Convention (BIOHK2024) was grandly opened. Frank Yang, Founding Partner & CEO of BOCG, was honored to join distinguished experts from the fields of investment, entrepreneurship, and medicine for a panel discussion on the theme, “Can Biotech Be Hong Kong’s Next Pillar of Growth?”
September 12, 2024
On September 10th, the 2024 Shenzhen Biomedical Industry Investment and Promotion Conference was successfully held. BOCG’s portfolio companies, Boan Biotech and Ribo Life Science, participated in the signing ceremony as partners, announcing their intent to establish a presence in Shenzhen. Frank Yang, Founding Partner and CEO of BOCG, was interviewed by several media outlets, sharing his insights on Shenzhen’s unique advantages and prospects for developing the biomedical industry as an innovative city in the Greater Bay Area.
July 24, 2024
Recently, BOCG's portfolio company, Innorna, announces that China National Medical Products Administration (NMPA) has granted a Drug Clinical Trial Approval Notice for its self-developed Herpes Zoster (HZ) mRNA vaccine IN001; meanwhile, U.S. FDA orphan drug designation granted to IN022 for the Treatment of Homocystinuria after it was granted rare pediatric disease designatio.
July 17, 2024
On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry.
July 9, 2024
BOCG's portfolio company Innorna has been granted the U.S. FDA Rare Pediatric Disease Designation (RPDD) for IN022, their investigational therapy for treating classic homocystinuria (HCU).
December 1, 2023
China’s Best Impact Investments of the Year Awards were solemnly announced, with BOCG winning the “2023 For Good Award | Top 10 Impact Investment Institution”. Dr. Yanling Wen, Chief Medical Officer of BOCG, was invited to participate in a roundtable forum to discuss the challenges and opportunities of ESG impact investment in China.
July 1, 2022
Four well-achieved experts with industry, academic and clinical background respectively, have joined its Scientific and Industrial Advisory Board ("The Advisory Board") to strengthen its investment and operational capabilities. They are Dr. Yan Shao, Dr. Yongqin Zeng, Prof. Jixi Li and Prof. Yanling Wen.
